References
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis: current approaches to diagnosis and treatment. N Engl J Med 1997; 337: 898–912
- Goenka MK, Bhasin DK, Vasisth RK, Dhawan S. Hepatic amyloidosis presenting with severe intrahepatic cholestasis. J Clin Gastroenterol 1996; 23: 134–6
- Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998; 42: 727–34
- Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002; 49: 1315–9
- Köklü S., Ödemis B, Cengiz C, Yüksel O, Üsküdar O, Turhan N. Fulminant hepatic failure due to secondary amyloidosis. Dig Liv Dis 2006; 38: 208–10
- Rajkumar SV, Dispenzieri A, Kyle R. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81: 693–703
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
- Bradwell A, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673–80
- Cross TJ, Wendon JA, Quaglia A, Salisbury JR, Heneghan MA, Harrison PM. Myeloma associated amyloidosis presenting as subacute liver failure. Postgrad Med J 2006; 82: e13
- Nagasawa T, Yanagisawa H, Hasegawa Y, Kanma H, Abe T. Polycythemia associated with primary systemic amyloidosis: elevated levels of hemopoietic factors and cytokines. Am J Hematol 1993; 43: 57–60
- Virally ML, Guillausseau PJ. Hypoglycemia in adults. Diabetes Metab 1999; 25: 477–90
- Snowden JA, Greaves M, Page K. Reversal of diabetes associated with escape of myeloma: evidence for inappropriate IGF-II secretion. Br J Haematol 1994; 87: 202–4
- Harris KP, Mackay EH, Walls J. Uraemic hypoglycaemia caused by adrenal amyloid. Lancet 1986; 1: 970–1
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with AL amyloidosis. Blood 1999; 93: 1062–6
- Müller A, Geibel A, Neumann H, Kühnemund A, Schmitt-Gräff A, Böhm J, et al. Primary (AL) amyloidosis in plasma cell disorders. Oncologist 2006; 11: 824–30
- Gertz MA, Kyle RA. Hepatic amyloidosis (primary AL immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85: 73–80
- Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004; 89: 717–41
- Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplant 2006; 38: 7–15
- Schechter G. A triple on AL amyloidosis, waiting for a home run. Blood 2007; 109: 391–2
- Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–82
- Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007; 356: 2413–5
- Gertz MA, Lacy MQ, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 2002; 61: 1–9
- Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–64
- Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–6
- Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 2007; 5: 179–87